赣南医科大学学报2025，Vol.45Issue(1)：37-44,8.DOI:10.3969/j.issn.1001-5779.2025.01.006
冠心病降脂治疗的研究进展
Progress of lipid-lowering therapy for coronary heart disease
胡远昌 1刘玉华 1邹青山 1谢东阳2
作者信息
- 1. 赣南医科大学第一临床医学院
- 2. 赣南医科大学第一附属医院心脏医学中心,江西 赣州 341000
- 折叠
摘要
Abstract
Dyslipidemia is the main pathogenic factor of coronary heart disease.It will lead to vascular endothelial cell damage and atherosclerosis,and then lead to coronary heart disease.Lipid-lowering therapy is one of the management strategies of coronary heart disease,which can reduce the formation and progress of atherosclerotic plaques,improve vascular function and reduce the occurrence of coronary heart disease.At present,there is still controversies over the selection of specific lipid-lowering schemes for different patients in clinical practice.By researching literature from both domestic and international sources,this review focuses on two aspects:the mechanisms by which different classes of lipid-lowering drugs regulate lipid metabolism and the selection of personalized lipid-lowering strategies for different patients.The literature review indicates that commonly used lipid-lowering drugs in clinical practice include statins,fibrates,cholesterol absorption inhibitors,pro-protein converting enzyme subtilisin 9(PCSK9)inhibitors,nicotinic acid and high-purity fish oil preparations,etc.While hese drugs have different mechanisms for lowering lipids,they all have a certain degree of lipid reduction.It is necessary to make personalized lipid management plans for patients with comorbidities such as hypertension,diabetes,chronic kidney disease,and pregnancy,which can reduce the risk of cardiovascular diseases like coronary heart disease,providing greater clinical benefits for patients.关键词
血脂异常/冠心病/降脂/药物Key words
Dyslipidemia/Coronary heart disease/Lipid lowering/Drugs分类
临床医学引用本文复制引用
胡远昌,刘玉华,邹青山,谢东阳..冠心病降脂治疗的研究进展[J].赣南医科大学学报,2025,45(1):37-44,8.
